Valiant Organics H1FY27 Results (NSE: VALIANTORG)

5 Nov 2026 · Analysis by Alpha Inflection

Signal: Margin expansion

The read

The trajectory remains a sharp recovery, with H1 revenue up 48.1% and EBITDA up 75.0%; the key inflection is Pharma's ₹2,625.01 lakh profit turnaround, although gross margin compressed 295bps as raw-material intensity rose to 63.28% and the asset base expanded faster than depreciation.

P&L walk

Consolidated revenue rose 48.1% YoY to ₹53,575.61 lakh, but gross margin fell to 38.58% from 41.51% as raw-material cost increased to 63.28% of revenue; EBITDA nevertheless rose 75.0% to ₹8,064.23 lakh as employee cost grew 13.3%, depreciation 6.9% and finance cost 0.1%, driving PAT up 235.8% to ₹4,655.89 lakh.

Segments

Pharma is the main inflection: revenue rose 63.4% to ₹14,163.60 lakh and segment result turned positive at ₹2,625.01 lakh from a ₹229.41 lakh loss, while Speciality Chemicals revenue rose 43.3% to ₹39,412.01 lakh and result rose 46.3% to ₹4,562.28 lakh.

Key positives

• Consolidated EBITDA rose 75.0% to ₹8,064.23 lakh versus revenue growth of 48.1%, a 26.9pp growth gap; employee cost grew 13.3%, depreciation 6.9% and finance cost 0.1%, with EBITDA margin expanding 232bps to 15.05%.
• Pharma segment result turned around from a ₹229.41 lakh loss to a ₹2,625.01 lakh profit while revenue grew 63.4% to ₹14,163.60 lakh.
• Finance cost remained nearly flat at ₹1,031.09 lakh despite revenue growth of 48.1%, and consolidated net debt declined by ₹92.96 lakh from March 2026.

Key concerns

• Gross margin compressed 295bps to 38.58% as raw-material cost increased to 63.28% of revenue from 61.26%; the filing does not disclose the driver or degree of pass-through.
• CWIP rose 92.1% to ₹4,064.17 lakh while PPE declined to ₹66,381.05 lakh, increasing execution and capitalisation monitoring needs.

View original filing

Research and educational content only. Not investment advice.